Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study

• Published in: Vaccine Vol. 34; no. 38; pp. 4579 - 4585
• Main Authors: Cramer, Jakob P., Dubischar, Katrin, Eder, Susanne, Burchard, Gerd D., Jelinek, Tomas, Jilma, Bernd, Kollaritsch, Herwig, Reisinger, Emil, Westritschnig, Kerstin
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 31.08.2016; Elsevier Limited
• Subjects: Age; Aged; Aged, 80 and over; Allergy and Immunology; antibodies; Antibodies, Viral - blood; Austria; children; Clinical trials; Disease; Elderly; Encephalitis; Encephalitis, Japanese - prevention & control; Female; Fever; Germany; headache; Hepatitis; Humans; immune response; Immunization, Secondary; Immunogenicity; Immunogenicity, Vaccine; Influenza; Japanese encephalitis; Japanese Encephalitis Vaccines - adverse effects; Japanese Encephalitis Vaccines - immunology; Japanese Encephalitis Vaccines - therapeutic use; Male; Older people; Population; Prospective Studies; Public health; Safety; Seroconversion; ticks; Tropical diseases; vaccination; Vaccine; Vaccines; Vector-borne diseases; viruses; Vaccine; Safety; Immunogenicity; Elderly; Japanese encephalitis

IXIARO® is a Vero cell-derived, inactivated Japanese encephalitis (JE) vaccine licensed mainly in western countries for children and adults traveling to JE endemic areas. Limited immunogenicity and safety data in elderly travelers have been available. To evaluate safety and immunogenicity of IXIARO...